White Papers

31. Case Studies In Accrual Prediction 4/22/2022

    Accrual is the ultimate outcome of success for a clinical trial. Gain insight into how without accrual, data cannot be obtained to answer the scientific objective being investigated.

32. Bringing Infectious Disease Studies To Patients 4/21/2022

    Learn how infectious disease trials successfully enroll patients utilizing a new kind of model that meets patients where they are through community healthcare and virtual settings.

33. Understanding Usability: Guidance For Gathering Complete, Unbiased Data From Wearables 4/21/2022

    A critical aspect of wearable-enabled clinical trials is usability, which covers a broad range of factors that need to be done well in order for sponsors to generate complete, unbiased participant data. This white paper serves as a free guide to understanding the impact each element of usability has on trial success.

34. Choosing An EDC With A Robust API For Digital Therapeutics (DTx) Clinical Trials 4/20/2022

    This white paper explores the importance of choosing an EDC with an API before starting a clinical trial.

35. Going Global With eConsent 4/20/2022

    Scott Askin paints the picture of why Novartis, determined to improve the patient experience, has begun to deploy eConsent, and what they’ve learned along the way.

36. Enabling Access To Novel Pharmacotherapy In Amyotrophic Lateral Sclerosis 4/20/2022

    In this white paper, learn why ensuring patient access to new ALS therapies requires more than regulatory approval of such therapies.

37. Patient-Centricity In Clinical Trial 4/20/2022

    Explore why now is the time for study leaders to take the next step toward delivering the best possible research experiences for patients by co-creating their studies with patients. 

38. How Monitoring & Data Management Transform Using eSource/EDC Vs. Traditional EDC 4/18/2022

    Discover an integrated eSource/EDC model, in which source data is collected electronically and then transmitted automatically, which in turn allows sponsors to review, query, code, lock, and extract the data.

39. Pharma R&D Annual Review 2022 Supplement: New Active Substances Launched During 2021 4/18/2022

    See the industry’s NAS success stories: new chemical or biological entities where the active ingredient had received no prior approval for human use. 

40. Characterizing The Use Of External Controls For Augmenting Randomized Control Arms And Confirming Benefit 4/14/2022

    Learn several approaches to constructing an external control while considering the use of hybrid designs that supplement or augment the control group in the randomized control trials (RCT) with data from an external population.